(Phenylamino)pyrimidine-1,2,3-triazole derivatives as analogs of imatinib: searching for novel compounds against chronic myeloid leukemia
| Autor: | Lucas Villas Bôas Hoelz, Anna C. Cunha, Frederico Silva Castelo Branco, Mônica M. Bastos, Henayle Fernandes Canzian, Nubia Boechat, Andressa Paula de Oliveira, Jackson A. L. C. Resende, Luiz Claudio Ferreira Pimentel, Vinícius R. Campos, Rafael Ferreira Dantas, Floriano Paes Silva Junior |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
1
2 3-Triazole Stereochemistry Chemistry Science Organic Chemistry Triazole Myeloid leukemia Imatinib Full Research Paper (phenylamino)pyrimidine-pyridine chemistry.chemical_compound QD241-441 Non-competitive inhibition imatinib Docking (molecular) chronic myeloid leukemia hemic and lymphatic diseases 1 3-dipolar cycloaddition medicine 1 2 3-triazole Tyrosine kinase medicine.drug K562 cells |
| Zdroj: | Beilstein Journal of Organic Chemistry Beilstein Journal of Organic Chemistry, Vol 17, Iss 1, Pp 2260-2269 (2021) |
| ISSN: | 1860-5397 |
| Popis: | The enzyme tyrosine kinase BCR-Abl-1 is the main molecular target in the treatment of chronic myeloid leukemia and can be competitively inhibited by tyrosine kinase inhibitors such as imatinib. New potential competitive inhibitors were synthesized using the (phenylamino)pyrimidine-pyridine (PAPP) group as a pharmacophoric fragment, and these compounds were biologically evaluated. The synthesis of twelve new compounds was performed in three steps and assisted by microwave irradiation in a 1,3-dipolar cycloaddition to obtain 1,2,3-triazole derivatives substituted on carbon C-4 of the triazole nucleus. All compounds were evaluated for their inhibitory activities against a chronic myeloid leukemia cell line (K562) that expresses the enzyme tyrosine kinase BCR-Abl-1 and against healthy cells (WSS-1) to observe their selectivity. Three compounds showed promising results, with IC50 values between 1.0 and 7.3 μM, and were subjected to molecular docking studies. The results suggest that such compounds can interact at the same binding site as imatinib, probably sharing a competitive inhibition mechanism. One compound showed the greatest interaction affinity for BCR-Abl-1 in the docking studies. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|